Somatic TP53 alterations are among the most frequent genetic lesions in CRC, reported in roughly 40–60% of tumors depending on cohort and assay, with a predominance of missense substitutions clustered in DNA-binding “hotspot” residues [24]. Here, TP53 is linked to colorectal carcinoma.